PMID- 29388082
OWN - NLM
STAT- MEDLINE
DCOM- 20190204
LR  - 20210109
IS  - 1559-1182 (Electronic)
IS  - 0893-7648 (Linking)
VI  - 55
IP  - 9
DP  - 2018 Sep
TI  - Brain-Derived Neurotrophic Factor Prevents Depressive-Like Behaviors in 
      Early-Symptomatic YAC128 Huntington's Disease Mice.
PG  - 7201-7215
LID - 10.1007/s12035-018-0890-6 [doi]
AB  - Huntington disease (HD) is a neurodegenerative disorder caused by an expanded CAG 
      repeat in the Huntington disease gene. The symptomatic stage of the disease is 
      defined by the onset of motor symptoms. However, psychiatric disturbances, 
      including depression, are common features of HD and can occur a decade before the 
      manifestation of motor symptoms. We used the YAC128 transgenic mice (which 
      develop motor deficits at a later stage, allowing more time to study depressive 
      behaviors without the confounding effects of motor impairment) to test the 
      effects of intranasal brain-derived neurotrophic factor (BDNF) treatment for 
      15 days in the occurrence of depressive-like behaviors. Using multiple 
      well-validated behavioral tests, we found that BDNF treatment alleviated 
      anhedonic and depressive-like behaviors in the YAC128 HD mice. Furthermore, we 
      also investigated whether the antidepressant-like effects of BDNF were associated 
      with an increase in adult hippocampal neurogenesis. However, BDNF treatment only 
      increased cell proliferation and neuronal differentiation in the hippocampal 
      dentate gyrus (DG) of wild-type (WT) mice, without altering these parameters in 
      their YAC128 counterparts. Moreover, BDNF treatment did not cause an increase in 
      the number of dendritic branches in the hippocampal DG when compared with animals 
      treated with vehicle. In conclusion, our results suggest that non-invasive 
      administration of BDNF via the intranasal route may have important therapeutic 
      potential for treating mood disturbances in early-symptomatic HD patients.
FAU - da Fonseca, Victor Silva
AU  - da Fonseca VS
AD  - Department of Morphological Sciences, Center of Biological Sciences, Federal 
      University of Santa Catarina, Florianopolis, SC, 88040-900, Brazil.
FAU - da Silva Colla, Andre R
AU  - da Silva Colla AR
AD  - Department of Biochemistry, Center of Biological Sciences, Federal University of 
      Santa Catarina, Florianopolis, SC, 88040-900, Brazil.
FAU - de Paula Nascimento-Castro, Cristine
AU  - de Paula Nascimento-Castro C
AD  - Department of Morphological Sciences, Center of Biological Sciences, Federal 
      University of Santa Catarina, Florianopolis, SC, 88040-900, Brazil.
FAU - Placido, Evelini
AU  - Placido E
AD  - Department of Morphological Sciences, Center of Biological Sciences, Federal 
      University of Santa Catarina, Florianopolis, SC, 88040-900, Brazil.
FAU - Rosa, Julia Macedo
AU  - Rosa JM
AD  - Department of Biochemistry, Center of Biological Sciences, Federal University of 
      Santa Catarina, Florianopolis, SC, 88040-900, Brazil.
FAU - Farina, Marcelo
AU  - Farina M
AD  - Department of Biochemistry, Center of Biological Sciences, Federal University of 
      Santa Catarina, Florianopolis, SC, 88040-900, Brazil.
FAU - Gil-Mohapel, Joana
AU  - Gil-Mohapel J
AD  - Division of Medical Sciences, UBC Island Medical Program, University of Victoria, 
      Victoria, BC, V8W 2Y2, Canada.
FAU - Rodrigues, Ana Lucia S
AU  - Rodrigues ALS
AD  - Department of Biochemistry, Center of Biological Sciences, Federal University of 
      Santa Catarina, Florianopolis, SC, 88040-900, Brazil.
FAU - Brocardo, Patricia S
AU  - Brocardo PS
AD  - Department of Morphological Sciences, Center of Biological Sciences, Federal 
      University of Santa Catarina, Florianopolis, SC, 88040-900, Brazil. 
      patricia.brocardo@ufsc.br.
LA  - eng
GR  - 480176/2013-2/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico/
PT  - Journal Article
DEP - 20180131
PL  - United States
TA  - Mol Neurobiol
JT  - Molecular neurobiology
JID - 8900963
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Administration, Intranasal
MH  - Animals
MH  - *Behavior, Animal
MH  - Brain-Derived Neurotrophic Factor/administration & 
      dosage/pharmacology/*therapeutic use
MH  - Cell Differentiation/drug effects
MH  - Cell Proliferation/drug effects
MH  - Dendrites/drug effects/metabolism
MH  - Depression/complications/*drug therapy/physiopathology/*prevention & control
MH  - Disease Models, Animal
MH  - Female
MH  - Hippocampus/drug effects/pathology
MH  - Humans
MH  - Huntington Disease/*complications/*pathology/physiopathology
MH  - Male
MH  - Mice, Transgenic
MH  - Motor Activity/drug effects
MH  - Neostriatum/drug effects/pathology
MH  - Recombinant Proteins/administration & dosage/pharmacology/therapeutic use
OTO - NOTNLM
OT  - Brain-derived neurotrophic factor (BDNF)
OT  - Depression
OT  - Hippocampus
OT  - Huntington's disease
OT  - Neurogenesis
OT  - YAC128 transgenic mice
EDAT- 2018/02/02 06:00
MHDA- 2019/02/05 06:00
CRDT- 2018/02/02 06:00
PHST- 2017/10/14 00:00 [received]
PHST- 2018/01/08 00:00 [accepted]
PHST- 2018/02/02 06:00 [pubmed]
PHST- 2019/02/05 06:00 [medline]
PHST- 2018/02/02 06:00 [entrez]
AID - 10.1007/s12035-018-0890-6 [pii]
AID - 10.1007/s12035-018-0890-6 [doi]
PST - ppublish
SO  - Mol Neurobiol. 2018 Sep;55(9):7201-7215. doi: 10.1007/s12035-018-0890-6. Epub 
      2018 Jan 31.